In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Redefining the Stem Cell Opportunity

Executive Summary

Small companies are now trying to leverage the value of both embryonic stem cells and adult stem cells, as genomics tools and for toxicology screening. At the same time, stem cells are gradually making their way into human testing, leading to an even more urgent need to understand the role that cytokines and growth factors play in signaling cells to differentiate. In fact, there's a growing recognition that the ultimate pharma opportunity may lie in selling drug cocktails that control cell differentiation, not in making and selling cells. Because dormant adult stem cells reside in tissues and in circulation, researchers are even beginning to envision applications where transplanted replacement cells are not needed at all.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel